Recent experiments using direct delivery of VEGF-C156S protein into the carotid artery after tMCAO resulted in larger brain infarcts at both 3 d- and 7 d-pso, compared with control-treated tMCAO mice, without an associated increase in lymphatic growth but with increased local infiltration of CD45+ and leukocytes in brain perivascular regions reported (Choi et al., 2023, Preprint). The gene discussed is VEGFA; the disease is brain infarction.